Scintigraphy

Having detailed and accurate information on how a drug product is distributed and absorbed in the human body is critical to assessing whether it will be safe and effective.

We have more than 19 years’ experience in drug product radiolabelling and gamma-scintigraphic image analysis. These imaging technologies are capable of visualising and quantifying regional deposition over time, from the moment the product is administered. PK and PD parameters can be assessed in parallel, providing important insight into what is possible for the development of a new drug.

We investigate the transit and disintegration of orally administered formulations. This information, assessed alongside PK data, gives specific guidance on the formulation strategy needed to achieve optimum oral delivery. The technology can also be used to understand how food affects drug delivery and how gut motility is impacted by drug administration. This forms part of safety/tolerance or pharmacological end-point analysis.

Using our proprietary radiolabeling techniques in combination with gamma scintigraphic image analysis, we can visualise and quantify human lung and nasal deposition. As a result, we deliver critical information about the in vivo performance of inhaled drugs.  Scintigraphic studies on inhaled products provide insight into the efficiency of different inhalation devices, the suitability of different inhaled formulations and guidance on appropriate dosing levels. They also identify safety concerns and highlight potential patient compliance issues, enabling simple regulatory compliance.